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Abstract
Staphylococcus aureus is a major cause of serious illness and death in children, indicating
the need to monitor prevalent strains, particularly in the vulnerable pediatric population.
Nasal carriage of S. aureus is important as carriers have an increased risk of serious illness
due to systemic invasion by this pathogen and can transmit the infection. Recent studies
have demonstrated the effectiveness of azithromycin in reducing the prevalence of naso-
pharyngeal carrying of pneumococci, which are often implicated in respiratory infections in
children. However, very few studies of the impact of azithromycin on staphylococci have
been undertaken. During a clinical trial under taken in 2016, nasal swabs were collected
from 778 children aged 3 to 59 months including 385 children who were swabbed before
administration of azithromycin or placebo and 393 after administration of azithromycin or
placebo. Azithromycin was given in a dose of 100 mg for three days, together with the anti-
malarials sulfadoxine-pyrimethamine and amodiaquine, on four occasions at monthly inter-
vals during the malaria transmission season. These samples were cultured for S. aureus as
well as for the pneumococcus. The S. aureus isolates were tested for their susceptibility to
azithromycin (15 g), penicillin (10 IU), and cefoxitine (30 g) (Oxoid Ltd). S. aureus was iso-
lated from 13.77% (53/385) swabs before administration of azithromycin and from 20.10%
(79/393) six months after administration (PR = 1.46 [1.06; 2.01], p = 0.020). Azithromycin
resistance found in isolates of S. aureus did not differ significantly before and after interven-
tion (26.42% [14/53] vs 16.46% [13/79], (PR = 0.62 [0.32; 1.23], p = 0.172). Penicillin resis-
tance was very pronounced, 88.68% and 96.20% in pre-intervention and in post-
intervention isolates respectively, but very little Methicillin Resistance (MRSA) was detected
(2 cases before and 2 cases after intervention). Monitoring antibiotic resistance in S. aureus
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and other bacteria is especially important in Burkina Faso due to unregulated consumption
of antibiotics putting children and others at risk.
Introduction
In 2018, despite progress over the past two decades, an estimated 5.3 million children under
five-year old died, mainly from preventable or treatable causes such as birth complications,
pneumonia, diarrhea, neonatal septicemia or malaria [1]. Sub-Saharan Africa remained the
region of the world with the highest under-five mortality rate. The average under-five mortal-
ity rate was 78 deaths per 1,000 live births resulting in the death of one in 13 children before
their fifth birthday [1].
In recent years, much attention has been paid to the potential of mass drug administra-
tion (MDA) of azithromycin (AZ) to reduce under-five mortality. Recent studies con-
ducted in Ethiopia and the MORDOR trial in Malawi, Niger and Tanzania showed that
MDA with AZ was associated with a significant reduction in child mortality, especially in
infants [2,3]. However, a trial conducted in Burkina Faso and Mali in which AZ was given
together with Seasonal Malarial Chemoprevention (SMC) drugs (sulfadoxine-pyrimeth-
amine plus amodiaquine) did not detect any reduction in deaths or hospital admissions
[4]. Several studies have documented the collateral effects of MDAs with AZ, including
the emergence of antimicrobial resistance, which is a global public health concern. Studies
on the acquisition of resistance after MDA have focused mainly on gut bacteria and Strep-
tococcus pneumoniae. Studies in Tanzania, Nepal, and Gambia have shown no evidence of
such resistance following a single treatment cycle [5–7]. Other studies have suggested that
resistance can emerges after a single round mass treatment [8,9]. Recently, a study in Bur-
kina Faso and Mali has shown the emergence of pneumococcal resistance after six semi-
annual cycles of administration of azithromycin which persisted for a year after the last
drug administration [10].
To date, little work has been done to assess the effect of AZ MDAs on other bacterial patho-
gens. A number of recent studies have looked at the gut resistome post azithromycin MDA
uch as placebo-controlled trials reported by Doan et al. [11,12] have shown rates of macrolide
resistance after multiple administrations of azithromycin that are approximately four times
higher in cases than in controls. The main bacteria causing invasive diseases in children were,
until fairly recently, S. pneumoniae and Haemophilus influenzae. However, following the wide-
spread use of conjugate vaccines against H. influenzae type b (Hib) and S. pneumoniae, Hib
infections have decreased significantly [13,14] and pneumococcal vaccine serotype infections
are decreasing also [15]. The decrease in the incidence of the disease associated with these two
pathogens has resulted in S. aureus becoming a relatively more common cause of invasive bac-
terial diseases than in the past [4].
In sub-Saharan Africa, S. aureus bacteremia is a common cause of invasive bacterial disease
in children. Hospital studies have shown that S. aureus is the most common cause of invasive
bacterial diseases in children under 5 years of age in Gambia and Nigeria [16,17].
This ancillary study to the trial conducted in Burkina Faso and Mali [4] has examined
the impact of azithromycin administration as a preventive treatment on the prevalence of
S. aureus nasopharyngeal carriage and its resistance to azithromycin. The impact of AZ
administration of carriage of S. pneumoniae in the same population has been reported pre-
viously [10].
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Study population and methods
Population
This study is a sub-study of a recently conducted trial which investigated the impact of adding
AZ to the antimalarial drugs used for Seasonal Malaria Chemoprevention (SMC) in Burkina
Faso and Mali [4]. In summary, 19,200 children aged from 3 to 59 months were randomized
to receive Sulfadoxine-Pyrimethamine (SP) and Amodiaquine (AQ) (Guilin Pharmaceutical,
Shanghai, China) with Azithromycin (AZ) (Cipla, Mumbai, India) or placebo (P). A household
census was conducted in June 2014, and children of either sex who were 3 to 59 months of age
on August 1, 2014, were eligible for enrollment in the trial. The household census was repeated
in May 2015 and in May 2016 to recruit additional eligible children and to detect any deaths
that had been missed through the surveillance system. The children were selected from all over
the Houndé region. Each year, children who were still younger than 60 months of age on
August 1 remained in follow-up for the subsequent trial year, and children who had reached 5
years of age on or before July 31 exited the trial on that date. Randomization was performed
according to household to avoid the potential effect of within household transmission of infec-
tion; all eligible children who shared a kitchen were assigned to the same trial group. To mask
the trial-group assignments for the trial team and caregivers, a placebo for azithromycin of
identical appearance was used. Infants aged 3 to 11 months received 250 mg/12.5 mg of SP
and 75 mg of AQ on day 1 and 75 mg of AQ on days 2 and 3. In addition, they received 100
mg of AZ or a AZ placebo on days 1, 2 and 3. Children between the ages of 1 and 4 received
double of these doses. The drug combination SP-AQ was provided by the pharmaceutical
company, Guilin Pharmaceutical (Shanghai, China) and Azithromycin and the corresponding
placebo were provided by the CIPLA laboratory (Mumbai, India). All treatment doses were
administered by trial staff. Coverage with monthly treatments was high, with more than 80%
of children receiving three or four treatment cycles each year. Deaths, hospital admissions and
clinic attendances were recorded throughout the study period [4]. Cross-sectional surveys
were conducted at the end of each malaria transmission season [4] (Fig 1).
Nasopharyngeal sampling
Nasopharyngeal swabs were obtained in 2014, 2015, and 2016 in July before AZ administration
and in December after administration each year (hereafter referred to as pre- and post- inter-
ventions samples). Only samples taken from pre- and post-2016 interventions were evaluated
for nasopharyngeal carriage of S. aureus. A total of 385 and 393 children, randomly selected
from the 10,636 children who participated in the trial in Burkina Faso provided samples before
and after administration of AZ or its placebo, respectively.
Swabs were taken from the posterior wall of a child’s nasopharynx using a calcium alginate
swab (FLOQSwabs™ Copan/USA) and immediately transferred to cryotubes containing a
milk-tryptone-glucose-glycerol (STGG) medium. These cryotubes were tagged and placed in a
cooler with ice packs before being transferred to the laboratory within eight hours of sampling
and they were then kept at -80 degrees Celsius until analysis.
Laboratory methods
The nasopharyngeal samples were thawed at room temperature and 10 μl of each sample were
inoculated on Chapman medium (Oxoid Ltd) and incubated for 24 hours at 37 degrees Cel-
sius. Presumed colonies of S. aureus, indicated by the presence of a golden yellow pigment,
were purified by cultivation on fresh agar containing 5% fresh sheep’s blood and incubated
under the same conditions. The coagulase agglutination test (Slidex Staph plus,
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BioMérieux1SA) was carried out on well-characterized colonies to confirm their identifica-
tion as S. aureus. Standard 0.5 McFarland S. aureus colony suspensions were seeded in Mueller
Hinton agar for the following antibiotic sensitivity tests: azithromycin (15 μg), penicillin (10
IU) and cefoxitin (30 μg) (Oxoid Ltd). Susceptibility results were interpreted in accordance
Fig 1. Screening, randomization, and follow-up.
https://doi.org/10.1371/journal.pone.0257190.g001
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with Clinical and Laboratory Standards Institute [18]. Azithromycin resistance (AzmR) was
defined by an inhibition diameter of 13 mm or less around the antibiotic disk, penicillin by an
inhibition diameter of 28 mm or less, and that of cefoxitin by a diameter of 21 mm or less.
Statistical considerations
The primary endpoint of the study was the prevalence of S. aureus carriage in intervention and
control groups. A secondary endpoint was the overall prevalence of AZ-resistant S. aureus isolates
in nasopharyngeal carriage. The evaluation criteria included an analysis of the sensitivity of staphy-
lococci to other antibiotics. Demographic and biologic data are shown as proportions and com-
pared by Pearson chi-square or Fisher’s exact test. Prevalence ratio estimated by Poisson regression
was used to compare prevalence. The significance threshold for all statistical tests was 0.05.
Ethical considerations
The study was approved by the Ethics Committee of the London School of Hygiene and Tropi-
cal Medicine and the Ethics Committee of the Ministry of Health of Burkina Faso. The pro-
spective study was recorded on Clinicaltrials.gov (NCT02211729). Written consent of the
parents or guardians was obtained for the inclusion of a child in the overall trial and for inclu-
sion in this sub-study.
Results
Study participants
A total of 385 children (193 in the Azithromycin group, and 192 in the placebo group) were
swabbed in 2016 before the intervention, and 393 (192 in the Azithromycin group and 201 in
the placebo group) were swabbed after the intervention. Demographic and biological data of
trial participants are given in Table 1. Only 7.07% of study participants carried both pneumo-
cocci and staphylococci.
Carriage with S. aureus
S. aureus carriage before and after intervention were shown in Table 2. There was no differ-
ence in S. aureus carriage between the AZ and placebo groups before intervention (p = 0.899)
or after the intervention (p = 0.267).
Frequency of azithromycin-resistant S. aureus
The overall frequency of S. aureus resistance to azithromycin (AzmR) was 26.42% ((14/ 53)
[CI 95% 16.15; 40.08] and 16.46% (13/79) [CI 95% 9.72; 26.49], respectively before and after
intervention. There was unable to find a significant difference in this relatively small sample.
Table 1. Socio-demographic characteristics of the study population.
Pre-intervention 2016 (before) Post intervention- 2016 (after)
Azithromycin N = 193 Placebo N = 192 p-value� Azithromycin N = 192 Placebo N = 201 p-value�
Age (years) group, n (%) <1 25 (13) 32 (16.67) 0.283 17 (8.85) 16 (7.96) 0.60
1–2 90 (46.63) 75 (39.06) 93 (48.44) 89 (44.28)
3–5 78 (40.41) 85 (44.27) 82 (42.71) 96 (47.76)
Males, n (%) 87 (45.08) 88 (45.83) 0.882 89 (46.35) 99 (49.25) 0.57
�p value for the comparison between AZ and placebo groups. Pearson chi-square test was used for these comparisons.
https://doi.org/10.1371/journal.pone.0257190.t001
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There was also no difference in S. aureus resistance according to the arm of treatment
(PR = 1.51 [0.74; 3.07], p = 0.259) (Fig 2A).
Frequency of resistance to other antibiotics
The overall prevalence of penicillin resistance (both arms combined) was very high—88.68%
[95% CI 76.72; 94.90] before and 96.20% [95% CI 88.70; 98.79] after the intervention
(PR = 1.08 [0.97, 1.21], 1.21] p = 0.137). Resistance to penicillin did not vary according to the
treatment arm (PR = 1.22 [0.98; 1.52], p = 0.076) (Fig 2B).
Only 4 cases of cefoxitin-resistant S. aureus (MRSA) were detected; two cases before the
intervention both in the azithromycin arm and two after intervention, one in each arm.
Discussion
S. aureus is a well-known pathogen whose resistance to most available antimicrobial agents is
increasing alarmingly. In this study, a 13.77% nasopharyngeal carriage rate of S. aureus was
found prior to the intervention, a similar prevalence of S. aureus carriage to that found in an
Ethiopian study in 2017 that reported a prevalence of 13% (52/400) among pre-school children
[19]. On the other hand, the rate found in this study was a little lower than that of a Ugandan
child population in the same age group with a carriage rate of 19.4% [20] or in a Ghanaian
population where it was 21% [21]. After mass administration of azithromycin in the commu-
nity, the prevalence of S. aureus carriage increased up to 20.10% in contrast to the carriage rate
of pneumococci in the same children which fell from 51.69% to 46.71% in 2016. Azithromycin
resistance for S. aureus did not increase after administration of the antibiotic overall or in
either arm (PR = 1.51 [0.74; 3.07], p = 0.259). In contrast this was not the case for pneumococ-
cal resistance, where an increase in azithromycin resistance was seen in children in the same
study and was more significant in children treated with azithromycin PR = 1,95 (1,05, 3,61)
P = 0,034 [10]. However, an effect might have been seen had AZ administration continued for
more than one year as was seen when resistance of pneumococci to AZ was followed for a lon-
ger period [10]. A high prevalence rate of resistance to penicillin was found with more than
90% of the strains produced penicillinase. This rate of resistance to S. aureus to penicillin is
similar to that reported in most Africa studies [19–22]. However, the resistance to cefoxitin
found in our study (4 cases) was lower estimates than in some other studies [22,23].
While it is one of the most common commensals in normal flora, S. aureus is a dangerous
pathogen that has developed resistance to nearly every new antibiotic introduced in half a century.
The plasticity of its genome gives the bacterium the ability to adapt to all environmental condi-
tions, including acquiring antibiotic resistance genes and developing regulatory mechanisms to
Table 2. Microbiological characteristics of the study population.
Pre-2016 (before) Post- 2016 (after)
Azithromycin N = 193 Placebo N = 192 P value Azithromycin N = 192 Placebo N = 201 P value
Recent antibiotic use, n(%) 13 (34.21) 13 (40.63) 0.580 8 (66.67) 9 (56.25) 0.705
S. pneumoniae (Sp) carriage, n(%) 95 (49.22) 103 (53.65) 0.442 84 (43.75) 99 (49.25) 0.311
Sp/AZ resistance, n(%) 9 (6.38) 11 (10.7) 0.761 22 (25.6) 13 (13.1) 0.034
S. aureus (S.a) carriage, n(%) 27 (13.99) 26 (13.54) 0.899 43 (22.40) 36 (17.91) 0.28
S.a/AZ resistance, n(%) 8 (29.63) 6 (23.08) 0.589 9 (20.93) 4 (11.11) 0.24
Double carriage, n(%) 10 (5.18) 12 (6.25) 0.651 17 (8.85) 16 (7.96) 0.75
�p value for the comparison between AZ and placebo groups. Pearson chi-square test was used for these comparisons.
https://doi.org/10.1371/journal.pone.0257190.t002
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adapt to increasing concentrations of antibiotics. Although MDA with azithromycin was not
found to lead to an increase in resistance of S. aureus to this antibiotic in this study; The relatively
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22. Walter S., Böck R., Antibiotic Resistance Trends of Nasal Staphylococcal Isolates from Namibian
School Children. Journal of Biosciences and Medicines, 2020. 8: p. 18–27.
23. Odutola A, C.Bottomley C., ZamanS A, et al, Staphylococcus aureus Bacteremia in Children of Rural
Areas of The Gambia, 2008–2015. Emerging Infectious Diseases, 2019. 25(4). https://doi.org/10.3201/
eid2504.180935 PMID: 30882307
PLOS ONE Mass administration of azithromycin and antibiotic resistance of Staphylococcus aureus
PLOS ONE | https://doi.org/10.1371/journal.pone.0257190 October 13, 2021 9 / 9
